RCS - Medpal AI PLC - Updated Research Note

Medpal AIAnnouncement

08/04/2026 12:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH6785Za&default-theme=true

RNS Number : 6785Z  Medpal AI PLC  08 April 2026

REACH non-regulatory announcement

8 April 2026

MedPal AI plc

(the "Company" or "MedPal AI")

Updated Research Note

MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health
company, is pleased to announce the release of an updated research note by
Optimo Research, alongside a new investor interview with CEO Jason Drummond.

 

On Thursday 2 April, Optimo Research Ltd updated its coverage of MedPal AI,
covering the significant progress made by the company since its IPO in August
2025.

 

The research can be downloaded on the Optimo Research website here:

 

https://www.optimocapital.co.uk/library-2
(https://www.optimocapital.co.uk/library-2)

 

In addition, in a new investor interview CEO Jason Drummond has shared how a
combination of AI-driven diagnostics, clinician access, and robotic dispensing
has enabled rapid growth, with over 200,000 prescription orders processed
since launch. The interview can be accessed on the ADVFN website here:

https://uk.advfn.com/market-news/article/14037/how-medpal-ai-scaled-to-40000-prescriptions-in-months-and-what-comes-next
(https://uk.advfn.com/market-news/article/14037/how-medpal-ai-scaled-to-40000-prescriptions-in-months-and-what-comes-next)

For further information please visit www.medpalplc.com
(http://www.medpalplc.com) or contact:

 

 MedPal AI plc

 Jason Drummond, Chief Executive Officer   Via Square1 Consulting

 Clear Capital Markets Limited             +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                        +44 (0) 20 7929 5599

 David Bick                                +44 (0) 7831 381201

 

About MedPal AI

 

MedPal AI is a UK-based digital health company building the MedPal Health OS -
a vertically integrated, closed-loop platform spanning AI wellness, clinical
services, and automated pharmacy fulfilment. Its core app aggregates data from
over 100 wearable devices and health apps (including Apple Health, Fitbit,
Garmin, and Whoop) into a unified health profile, offering personalised,
non-clinical lifestyle guidance through its AI wellness coach and acting as
the consumer front door to the Company's clinical and pharmacy services.

 

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages BD Rowa VMAX
robotic dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

 

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms.

 

The Company's LEI is 984500EDP8B0A14CBA61.

 

 

Follow us on social media:

X: @MedPalPlc

LinkedIn: MedPal AI plc

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only/non-regulatory news releases Into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or any other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFVLSSITIIR



            Copyright 2019 Regulatory News Service, all rights reserved